2C-T-17

Last updated

2C-T-17
2C-T-17 2DACS.svg
2C-T-17-3d-sticks.png
Clinical data
Other names4-sec-Butylthio-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-sec-butylthiophenethylamine; NIMITZ; Nimitz
Routes of
administration 		Oral [1]
Drug class Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action 10–15 hours [1]
Identifiers
  • 2-(4-butan-2-ylsulfanyl-2,5-dimethoxyphenyl)ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C14H23NO2S
Molar mass 269.40 g·mol−1
3D model (JSmol)
  • CC(CC)Sc1cc(OC)c(cc1OC)CCN
  • InChI=1S/C14H23NO2S/c1-5-10(2)18-14-9-12(16-3)11(6-7-15)8-13(14)17-4/h8-10H,5-7,15H2,1-4H3 Yes check.svgY
  • Key:KSZHVRPGICAZOA-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

2C-T-17, also known as 4-sec-butylthio-2,5-dimethoxyphenethylamine or as Nimitz, is a psychedelic drug of the phenethylamine and 2C families. [1] It is taken orally. [1]

Contents

2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991. [2] Shortly after this, Shulgin described 2C-T-17 in greater detail in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). [1]

Use and effects

According to Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved), 2C-T-17's dose range is 60 to 100 mg and its duration is 10 to 15 hours. [1] Its onset is 1 hour and peak effects occurred after 3 hours. [1] 2C-T-17 has been described as a "truly heavy psychedelic" but as producing no psychedelic visuals and very little in the way of perceptual changes. [1] User reports described it as having pronounced psychoactive effects but had difficulty describing exactly what those effects were. [1]

Toxicity

The toxicity of 2C-T-17 is not well-documented.[ citation needed ] It is much less potent than 2C-T-7, but it may be expected that at very high doses it would display similar toxicity to that of other phenethylamines of the 2C-T family.[ citation needed ]

Interactions

Pharmacology

Pharmacodynamics

The mechanism of action that produces 2C-T-17's hallucinogenic effects has not been specifically established, however it is most likely to result from action as a serotonin 5-HT2A receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.[ citation needed ]

Chemistry

2C-T-17 is the 2 carbon homologue of Aleph-17, which has never been synthesized. [1] The full chemical name is 2-[4-(2-butyl thio)-2,5-dimethoxy phenyl]ethanamine. [1] The drug has structural properties similar to drugs in the 2C-T series, with the most closely related compounds being 2C-T-7 and 2C-T-8. [1]

History

2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in a journal article in 1991. [2] Shortly thereafter, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). [1]

Society and culture

Canada

As of October 31, 2016, 2C-T-17 is a controlled substance (Schedule III) in Canada. [3]

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act. [4]

United States

2C-T-17 is not illegal, but possession and sales of 2C-T-17 could be prosecuted under the Federal Analog Act in the United States because of its structural similarities to 2C-T-7.

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628.
  2. 1 2 Shulgin AT, Shulgin A, Jacob P (January 1991). "Central nervous system (CNS) activity of two new psychoactive compounds". Journal of Psychoactive Drugs. 23 (1): 95–96. doi:10.1080/02791072.1991.10472583. eISSN   2159-9777. PMID   1941371. Archived from the original on 2025-07-13.
  3. ↑ "Canada Gazette – Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". 4 May 2016.
  4. ↑ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.